ERCC1 and XPF expression in human testicular germ cell tumors

Oncology Reports

Volumn 23, Issue 1, 2010, Pages 223-227

  Köberle, Beate ^a   Brenner, Walburgis ^a   Albers, Andreas ^b   Usanova, Svetlana ^a   Thüroff, Joachim W ^a   Kaina, Bernd ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Non seminomas; Nucleotide excision repair; Protein overexpression; Seminomas; Testis tumor development

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; NUCLEIC ACID BINDING PROTEIN; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP F PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEMINOMA; UPREGULATION;

ADULT; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; SEMINOMA; TESTICULAR NEOPLASMS; TESTIS; UP-REGULATION;

EID: 76049093837     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000627     Document Type: Article

References (31)

1. Bosl GJ and Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337: 242-253, 1997.
2. Horwich A, Shipley J and Huddart R: Testicular germ-cell cancer. Lancet 367: 754-765, 2006.
3. Oosterhuis JW and Looijenga LH: Testicular germ cell tumours in a broader perspective. Nat Rev Cancer 5: 210-223, 2005.
4. Di Pietro A, De Vries EGE, Gietema JA, Spierings DCJ and De Jong S: Testicular germ cell tumours: the paradigm of chemosensitive solid tumours. Int J Biochem Cell Biol 37: 2437-2456, 2005.
5. Honecker F, Oosterhuis JW, Mayer F, Hartmann JT, Bokemeyer C and Looijenga LH: New insights into the pathology and molecular biology of human germ cell tumors. World J Urol 22: 15-24, 2004.
6. Jones RH and Vasey PA: New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. Eur J Cancer 39: 147-156, 2003.
7. Feldman DR, Bosl GJ, Sheinfeld J and Motzer RJ: Medical treatment of advanced testicular cancer. JAMA 299: 672-684, 2008.
8. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
9. Masters JR and Köberle B: Curing metastatic cancer: lessons from testicular germ-cell tumours. Nature Rev Cancer 3: 517-525, 2003.
10. Kartalou M and Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 478: 23-43, 2001.
11. Gillet LC and Schärer OD: Molecular mechanisms of mammalian global genome nucleotide excision repair. Chem Rev 106: 253-276, 2006.
12. McHugh PJ, Spanswick VJ and Hartley JA: Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2: 483-490, 2001.
13. Sijbers AM, De Laat WL, Ariza RR, et al: Xeroderma pigmentosum group F caused by a defect in a structure-specific DNA repair endonuclease. Cell 86: 811-822, 1996.
14. Niedernhofer LJ, Odijk H, Budzowska M, et al: The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787, 2004.
15. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
16. Jun HJ, Ahn MJ, Kim HS, et al: ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemotherapy. Br J Cancer 99: 167-172, 2008.
17. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C and Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517, 1992.
18. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708, 1994.
19. Metzger R, Leichman CG, Danenberg KD, et al: ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16: 309-316, 1998.
20. Lord RV, Brabender J, Gandara D, et al: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8: 2286-2291, 2002.
21. Welsh C, Day R, McGurk C, Masters JR, Wood RD and Köberle B: Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 110: 352-361, 2004.
22. Bronson DL, Andrews PW, Solter D, Cervenka J, Lange PH and Fraley EE: Cell line derived from a metastasis of a human testicular germ cell tumor. Cancer Res 40: 2500-2506, 1980.
23. Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H and Donner J: Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer 11: 765-773, 1973.
24. Köberle B, Masters JR, Hartley JA and Wood RD: Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9: 273-276, 1999.
25. Sijbers AM, Vader PCV, Snoek JW, Raams A, Jaspers NGJ and Kleijer WJ: Homozygous r788w point mutation in the xpf gene of a patient with xeroderma-pigmentosum and late-onset neurologic disease. J Invest Dermatol 110: 832-836, 1998.
26. Stoop H, van Gurp R, De Krijger R, et al: Reactivity of germ cell maturation stage-specific markers in spermatocytic seminoma: diagnostic and etiological implications. Lab Invest 81: 919-928, 2001.
27. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER and Latif F: Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and non-seminoma testicular germ cell tumour. Oncogene 22: 461-466, 2003.
28. Yagi T, Wood RD and Takebe H: A low content of ERCC1 and a 120-kDa protein is a frequent feature of group F xeroderma pigmentosum fibroblast cells. Mutagenesis 12: 41-44, 1997.
29. Biggerstaff M, Szymkowski DE and Wood RD: Co-correction of the ERCC1, ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro. EMBO J 12: 3685-3692, 1993.
30. Nikolova T, Christmann M and Kaina B: FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res 29: 2453-2459, 2009.
31. Nagel G, Brenner W, Johnsson K and Kaina B: DNA repair protein O6-methylguanine-DNA methyltransferase in testis and testicular tumors as determined by a novel non-radioactive assay. Analyt Biochem 321: 38-43, 2003.